ZYBERNO
Stock Report
Updated Jun 4, 2026

INOZYME PHARMA, INC. (INZY)

Healthcare • NASDAQ

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
INOZYME PHARMA, INC. (INZY) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-160.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.67x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-777.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

INOZYME PHARMA, INC. (INZY) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, INZY generated -$96.55M in Owner Earnings. Capital was deployed as follows: $30.00K invested in capital expenditures. Reinvestment rate: 0.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$0.00

Enterprise Metrics (1)

Enterprise Value:-$38.52M
B. Profitability Assessment

Return Metrics (5)

ROA:-82.5%
Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-6.2%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:-999.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-278.6%
Latest Earnings Filed:2025-05-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.19x
Quick Ratio:2.19x
Cash Ratio:1.98x

Leverage Analysis (3)

Debt To Equity Ttm:0.67x
Debt-to-Equity Ratio:0.67x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-18.45x
Times Interest Earned:-18.45

Capital Structure (4)

Working Capital:50,856,000.00
Cash And Cash Equivalents:84,800,000.00
Long Term Debt:$20.59M
Net Debt:-$38.52M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$107.37M

Bottom Line Performance (3)

-$106.72M
Income Before Tax:$0.00
Ebitda Ttm:-106,679,000.00

Operating Expenses (5)

Operating Expenses:107,373,000.00
R And D Expense:84,499,000.00
Sga Expense:20,974,000.00
Income Tax Expense:$0.00
Interest Expense:5,639,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$95.16M
Current Assets:$93.64M
Ppe Net:608,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:63,366,000.00
Current Liabilities:42,781,000.00
Long Term Debt:$20.59M
Short Term Debt:$25.70M

Equity & Capital (3)

Equity:$31.80M
Retained Earnings:-$415.99M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:12,742,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,857,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$96.52M-$96.55M

Investment Activities (2)

Investing Cash Flow:$33.68M
Capital Expenditures Ttm:30,000.00

Financing Activities (3)

Financing Cash Flow:$228.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:228,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:694,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.68
-$1.68
Earnings Per Share Ttm:-$1.66

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.43

Book Value & Capital (2)

Book Value Per Share:$0.49
Cash Per Share:1.32

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$96.55M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.8%
Fundamental Growth Rate (g):-6.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-18.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:INZY
Company Name:INOZYME PHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:64.28M
Shares Outstanding Basic:64.28M
Shares Outstanding Diluted:64.28M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-04 12:40:45 UTC
Data Timestamp:2026-06-04T12:40:45.948247
Scroll to Top